DBV Technologies: makes bigger net loss in 2017
(CercleFinance.com) - DBV Technologies has posted a net loss of 147.
7 million euros for 2017, against a net loss of 114.5 million a year earlier.
Losses per share therefore reached respectively 5.97 euros and 4.68 euros in 2017 and 2016.
Operating income rose 31.1% to 11.9 million euros, although research and development expenses increased by 33.5% to 105.2 million euros, with commercial expenses increasing by 40.3% to 15.8 million euros.
The cash position of the biopharmaceutical company, which is specialised in epicutaneous immunotherapy, reached 137.9 million euros at 31 December 2017 compared with 256.5 million euros a year earlier, down 118.6 million euros.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
7 million euros for 2017, against a net loss of 114.5 million a year earlier.
Losses per share therefore reached respectively 5.97 euros and 4.68 euros in 2017 and 2016.
Operating income rose 31.1% to 11.9 million euros, although research and development expenses increased by 33.5% to 105.2 million euros, with commercial expenses increasing by 40.3% to 15.8 million euros.
The cash position of the biopharmaceutical company, which is specialised in epicutaneous immunotherapy, reached 137.9 million euros at 31 December 2017 compared with 256.5 million euros a year earlier, down 118.6 million euros.
Copyright (c) 2018 CercleFinance.com. All rights reserved.